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Human cytochrome P-450, UDP-glucuronosyltransferase and sulphotransferase activities have been mea- 
sured in the cell line Hep G2 following treatment of cells with 3-methylcholanthrene or phenobarbital. 
3-Methylcholanthrene treatment caused a 20-30-fold increase in the 0-deethylation of 7-ethoxycoumarin. 
The glucuronidation and sulphation of the product 7-hydroxycoumarin were increased 36 and 7 fold, re- 
spectively. In comparison. phenobarbital treatment did not increase these activities significantly. However, 
phenobarbital-inducible proteins were identified on ‘Western blots’ using antibodies to a rat liver phenobar- 
bital inducible P-450 form. The molecular masses of the proteins did not coincide with those expected for 
cytochromes P-450. However, characteristic of P-450 forms, the synthesis of these proteins was suppressed 
by 3-methylcholanthrene treatment. The Hep G2 cell line represents a potentially useful model for studying 
the regulation of human P-450 genes. 
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1. INTRODUCTION 
The ability to metabolise xenobiotics is a func- 
tion normally lost by liver cells in culture [l-3]. 
The activity drops to approximately 25% of the in 
vivo level within the first 24 h (e.g., [2,3]). This 
loss of drug metabolising activity coincides with 
the loss of a number of other specialised functions 
and appears to be a form of de-differentiation of 
the cells [3]. The Hep G2 cell line is an immortal- 
ised liver cell line of human origin [4]. These cells 
have been found to retain many of the specialised 
functions which are usually lost upon culturing. 
These functions include synthesis and secretion of 
major plasma proteins including cyZplasmin in- 
hibitor, apolipoproteins and insulin-like growth 
factor carrier protein [5-91; synthesis of hepatitis 
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B surface antigen [4,7] and metabolic activation of 
benzo(a)pyrene [lo]. The purpose of the present 
investigation was to evaluate whether this cell line 
could be used as a model for the study of the 
regulation of human drug metabolizing enzymes. 
2. MATERIALS AND METHODS 
Umbelliferone, 7-ethoxycoumarin, sulphatase 
(type H-5) and fi-glucuronidase solution 
(glucurase) were purchased from Sigma, Poole, 
Dorset. All other chemicals were of Analar reagent 
grade, purchased through local chemical suppliers. 
Hep G2 cells were kindly donated by Dr B. 
Knowles of the Wistar Institute, Philadelphia. 
The cells were grown in 75 cm2 flasks in 
RPM1 1640 containing 5% fetal calf serum and 
0.03% glutamine at 37°C in an atmosphere of 
humidified air containing 5% CO2 until there were 
approximately 10’ cells per flask. To each flask 
3-methylcholanthrene (5 FM) (3-MC) as a solution 
in dimethyl sulphoxide, or sodium phenobarbital 
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(1 mM) was added. No additions were made to 
control flasks. Three or four days after addition of 
inducing agents, the cells were harvested by addi- 
tion of trypsin, counted and washed repeatedly 
with fresh cell culture medium to remove the 
trypsin. 
For drug metabolism studies the cells were 
resuspended in cell culture medium, to which 
7-ethoxycoumarin (250pm) had been added, at a 
concentration of approx. lo6 cells/ml. The cells 
were incubated in 25 ml conical flasks in a shaking 
water bath at 37°C. At the relevant times, an ali- 
quot (2 ml) was withdrawn from each flask and 
placed in a screw-capped tube on ice. To the tube 
was added 7 ml ice-cold etheriisoamyl alcohol 
(1.5%; v/v) and the tubes extracted for 10 min us- 
ing a tube rotator. A portion (5 ml) of the ether 
layer was then back extracted into 3.5 ml 
glycine/NaOH buffer (0.2 M, pH 10.4) and the 
fluorescence of the aqueous layer was determined 
at 370/450 nm using a Perkin Elmer spec- 
trofluorimeter (see [l l] for method). Acetate/ 
acetic acid buffer (0.5 ml, 0.1 M, pH 4.8) and 
glucurase (0.5 ml) was added to the aqueous layer 
remaining after the ether extraction. The tubes 
were incubated overnight at 37°C and the free 
7-hydroxycoumarin released was extracted and 
assayed as described above. To the aqueous layer 
remaining after this second ether extraction, 
sulphatase in acetate/acetic acid buffer (30 units/ 
tube) was added and the tubes incubated and ex- 
tracted as above. A set of standard and control 
tubes was also taken through the extraction pro- 
cedure. Standards of 0.1 nmol7-hydroxycoumarin 
per ml were used. 
Western blots were carried out using antibodies 
to purified forms of rat liver cytochromes P-450, 
PBr, PB2, MC!1 and MC2 [12,13]. These antibodies 
have previously been shown to react with P-450 
isozymes present in human liver [14]. The method 
has been described previously [14] except that 
whole cells instead of microsomal fractions were 
used with 3Opg of cellular protein per lane. Pro- 
tein determinations were by the method of Lowry 
et al. [15]. 
3. RESULTS 
Metabolism of 7-ethoxycoumarin by untreated 
and phenobarbital-treated Hep G2 cells was 
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characterised by a marked lag period of approx. 
1-2 h (fig.la,b); the metabolism was then essen- 
tially linear. No lag period was measured with 
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Fig. 1. 7-Ethoxycoum~in metabolism in untreated Hep 
G2 cells (a) or cells following treatment with 
phenobarbital (b) or 3-MC (c). Experimental details are 
given in section 2. 
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3-MC-treated cells and the 0-deethylation of 
7~thoxycoumarin was linear with time (fig.lc), 
Glucuronidation of the ‘I-hydroxycoumarin re- 
leased by the P-450-mediated 0-deethylation was 
the dominant conjugation pathway, sulphation be- 
ing virtually undetectable (fig.l). Note that the 
P-450 metabolism was much more active than con- 
jugation in all cell samples. 
Treatment of the Hep G2 cells with phenobar- 
bital for 4 days prior to the 7-ethoxycoumarin 
assay resulted in a small increase in P-450 activity 
(124% of control), but this increase was not 
significant. Glucuronidation by phenobarbital- 
induced cells was also slightly increased. However, 
treatment of the Hep G2 cells with 3-MC (5 PM) 
.a. 6’. c 
Fig.2. Western blot of Hep G2 cells (30 pg/track) using 
an antibody to rat liver P-450 PBz. (a) Control cells, (b) 
cells treated with phenobarbital, (c) cells treated with 
3-methylchoIanthr~ne. Other details are given in section 
2. 
resulted in a very marked, 20-30-fold, increase in 
P-450-mediated metabolism (fig. lc). There was 
also a 38-fold increase in glucuronide conjugation 
and a g-fold increase in sulphate conjugation in 
3-MC-treated cells (fig.lc). The use of 3-MC at a 
concentration of 15 pM was cytotoxic to the Hep 
G2 cells (not shown). In Western blots of Hep G2 
cells with antibodies to 4 rat liver cytochrome 
P-450 isozymes, two induced by phenobarbital 
(PBr and PB2) [13] and two induced by 3-MC 
(MCI and MCz) [ 121, only the antibody to PB2 
gave positive results (fig.2). Two proteins were 
identified, with molecular masses of 64 and 
63 kDa. Both proteins were slightly induced by 
phenobarbital and suppressed by treatment with 
3-MC. 
4. DISCUSSION 
Although there have been reports of the induc- 
tion of drug metaboIi~ng enzymes in cell lines 
from other species HO], this is the first report of in- 
duction in cell lines of human origin. Both 
cytochrome P-450-dependent monooxygenase ac- 
tivity as well as UDP-glucuronosyltransferase ac- 
tivity were signi~can~y increased by treatment of 
the Hep G2 cells with 3-methylcholanthrene. 
In untreated Hep G2 cells, conjugating activity 
was low with glucuronidation more active than 
sulphation (fig. 1). In hepatocytes, sulphate con- 
jugation represents a major pathway at low 
substrate concentrations (similar to those used 
here) [16]. It has been reported that normal human 
lung tissue more readily sulphates than 
glu~uronidates phenol substrates. However, in 
cancerous tissue, glucuronidation is the major 
pathway [17,18]. The Hep G2 cell line originates 
from a biopsy sample from a primary 
hepatoblastoma, so the lack of sulphate conjuga- 
tion by these cells could be associated with their 
cancerous origin [ 1 J. 
Attempts to identify the P-450 isozymes present 
in these cells have not proved very successful. We 
have recently demonstrated that the antibodies to 
the rat liver P-450 isozymes used here will react 
with human liver microsomal samples, the 
strongest reactivity being with the antibodies to the 
phenobarbital-inducible proteins PBr and PB2 
1141. The only ~tibody to react with the Hep G2 
cells was the antibody to PBz. However, the pro- 
221 
Volume 183, number 2 FEBS LETTERS April 1985 
teins identified had higher molecular masses than 
those normally associated with P-450 forms. Con- 
sistent with P-450 forms, however, these protein 
bands were induced by phenobarbital and sup- 
pressed by 3-MC [14]. Unusual glycosylation of 
proteins in Hep 3B cells (another human hepatoma 
cell line) has been reported [19] which could ex- 
plain the high M, bands observed here. However, 
this possibility remains to be clarified. 
The regulation of cytochromes P-450 and UDP- 
glucuronosyltransferases in an immortalized cell 
line of human origin, such as Hep G2, is of con- 
siderable potential value both in the study of the 
properties of human drug metabolizing enzyme 
systems as well as in the testing of potential car- 
cinogens, for mutagenic activity, where a more ac- 
curate estimate of risk to man could be obtained. 
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